Flu Shots Market
Flu Shots Market Size, Share & Trends Analysis Report by Vaccine Type (Inactivated Influenza Vaccines (IIV), and Recombinant Influenza Vaccines), by Formulation (Trivalent Flu Shots, and Quadrivalent Flu Shots), and by Patient Group (Pediatric, Adult, and Geriatric), Forecast Period (2026-2035)
Industry Overview
Flu shots market was valued at $9.20 billion in 2025 and is projected to reach $18.30 billion by 2035, growing at a CAGR of 7.2% during the forecast period (2026-2035). The global flu shots market is growing due to the sustained burden of seasonal influenza and the continued emphasis on preventive vaccination as a core public health measure. Recurrent influenza outbreaks across both developed and emerging economies have reinforced the need for annual immunization, supporting consistent demand across pediatric, adult, and geriatric populations. In parallel, government-led immunization programs and procurement initiatives play a central role in expanding vaccine coverage, particularly through national vaccination schedules and publicly funded campaigns. These programs improve access, reduce cost barriers, and provide demand stability for manufacturers across multiple regions.
Market Dynamics
Shift Toward Quadrivalent and Advanced Inactivated Influenza Vaccines
The global flu shots market is witnessing a clear shift toward quadrivalent and advanced inactivated influenza vaccines, driven by their broader strain coverage compared to trivalent formulations. Healthcare authorities and immunization programs increasingly prefer quadrivalent vaccines to address the co-circulation of multiple influenza A and B strains within a single season. This transition supports higher adoption rates among healthcare providers, as it reduces uncertainty in strain selection and improves alignment with public health guidelines. Manufacturers continue to prioritize these formulations within their portfolios, reinforcing their role as a key growth segment. As a result, quadrivalent inactivated vaccines are becoming a standard offering in several national vaccination programs.
Rising Focus on High-Risk and Aging Populations
The expanding geriatric population is shaping demand patterns within the global flu shots market, as older adults face a higher risk of severe influenza-related complications. Public health agencies increasingly emphasize targeted vaccination coverage for elderly individuals and those with chronic conditions, strengthening demand within this patient group. This focus supports the uptake of specialized flu shots designed to enhance immune response in older populations. In parallel, healthcare systems are improving outreach and vaccination rates among high-risk groups through structured seasonal campaigns. These efforts contribute to sustained volume growth and reinforce the market’s dependence on demographic-driven demand.
Market Segmentation
- Based on the vaccine type, the market is segmented into inactivated influenza vaccines (IIV), and recombinant influenza vaccines.
- Based on the formulation, the market is segmented into trivalent flu shots, and quadrivalent flu shots.
- Based on the patient group, the market is segmented into pediatric, adult, and geriatric.
Inactivated Influenza Vaccines (IIV) Drive Core Demand Within the Vaccine Type Segment
Inactivated Influenza Vaccines (IIV) represent the largest and most established sub-segment within the Global flu shots market due to their long-standing regulatory acceptance and widespread clinical use. These vaccines are routinely recommended across pediatric, adult, and geriatric populations, supporting broad and recurring demand each influenza season. Public immunization programs and bulk government procurement predominantly rely on IIVs, reinforcing their volume leadership in the market. Their compatibility with both trivalent and quadrivalent formulations further strengthens their commercial relevance. As a result, IIVs continue to form the backbone of global influenza vaccination strategies.
Quadrivalent Flu Shots Gain Traction Within the Formulation Segment
Quadrivalent flu shots are emerging as a leading formulation sub-segment in the global flu shots market due to their expanded protection against two influenza A and two influenza B strains. Health authorities increasingly favor quadrivalent vaccines to address unpredictable strain circulation patterns, driving higher adoption in national vaccination schedules. This preference supports replacement demand, as quadrivalent products progressively displace trivalent alternatives in several regions. Manufacturers are aligning production capacity toward quadrivalent formulations to meet evolving procurement requirements. Consequently, this sub-segment is contributing to value growth and portfolio expansion within the overall market.
Regional Outlook
The global flu shots market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Remains the Leading Region in the Global Flu Shots Market
North America continues to hold a leading position in the global flu shots market, supported by high vaccination coverage, structured immunization policies, and strong public awareness of seasonal influenza prevention. The presence of well-established annual vaccination programs across the US and Canada ensures stable and recurring demand across all patient groups. Government-backed procurement, employer-led vaccination initiatives, and broad insurance coverage further strengthen market penetration. The region also benefits from the strong presence of major vaccine manufacturers with advanced production and distribution capabilities.
Asia-Pacific Emerges as the Fastest-Growing Region in the Global Flu Shots Market
Asia-Pacific is the fastest-growing region in the global flu shots market, driven by expanding immunization coverage, rising healthcare expenditure, and increasing awareness of influenza-related risks. Large population bases in countries such as China and India create significant demand potential, particularly as governments scale up seasonal vaccination initiatives. Improving access to healthcare services and the gradual inclusion of influenza vaccines in public health programs are accelerating market uptake. The region is also witnessing increased local manufacturing capacity, supporting supply availability and cost efficiency. These developments position Asia-Pacific as a key growth engine for the market over the forecast period.
Market Players Outlook
The major companies operating in the global flu shots market include CSL Ltd. (Seqirus), GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In January 2026, Moderna submitted regulatory applications for its investigational seasonal flu vaccine, mRNA-1010, targeting adults 50+, to the FDA, EMA, Health Canada, and Australia's TGA.
- In July 2025, GSK plc began shipping its trivalent seasonal flu vaccines, FLULAVAL and FLUARIX, to US healthcare providers and pharmacies for the 2025-26 flu season. This follows FDA licensing and lot-release approval. Both vaccines come in 0.5mL single-dose pre-filled syringes and are approved for individuals aged six months and older.
- In July 2025, CSL Seqirus, a CSL business, started shipping its influenza vaccines for the 2025/26 US season. As a global leader in flu prevention, the company emphasizes timely delivery to help protect individuals from influenza and its complications.
- In May 2024, Sanofi and Novavax entered a co-exclusive licensing agreement for Novavax’s adjuvanted COVID-19 vaccine. Sanofi will co-commercialize the vaccine globally, excluding countries with existing agreements and certain Asian markets. Sanofi also gains a sole license to combine Novavax’s COVID-19 vaccine with its flu vaccines, plus a non-exclusive license to use Novavax’s Matrix-M adjuvant.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global flu shots market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Flu Shots Market Sales Analysis – Vaccine Type | Formulation | Patient Group ($ Million)
- Flu Shots Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Flu Shots Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Flu Shots Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Flu Shots Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Flu Shots Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Flu Shots Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Flu Shots Market Revenue and Share by Manufacturers
- Flu Shots Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- CSL Ltd. (Seqirus)
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- GlaxoSmithKline plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co., Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sanofi
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- CSL Ltd. (Seqirus)
- Key Company Analysis
- Global Flu Shots Market Sales Analysis by Vaccine Type ($ Million)
- Inactivated Influenza Vaccines (IIV)
- Recombinant Influenza Vaccines
- Global Flu Shots Market Sales Analysis by Formulation ($ Million)
- Trivalent Flu Shots
- Quadrivalent Flu Shots
- Global Flu Shots Market Sales Analysis by Patient Group ($ Million)
- Pediatric
- Adult
- Geriatric
- Regional Analysis
- North American Flu Shots Market Sales Analysis – Vaccine Type | Formulation | Patient Group | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Flu Shots Market Sales Analysis – Vaccine Type | Formulation | Patient Group | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Flu Shots Market Sales Analysis – Vaccine Type | Formulation | Patient Group | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Flu Shots Market Sales Analysis – Vaccine Type | Formulation | Patient Group | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbott Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bharat Biotech International Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BIKEN Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- CSL Ltd. (Seqirus)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Daiichi Sankyo Company, Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Emergent BioSolutions Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Green Cross Corp. (GC Biopharma)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hualan Biological Engineering Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mitsubishi Tanabe Pharma Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Moderna, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novavax, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Serum Institute of India Pvt. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shanghai Institute of Biological Products Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sinovac Biotech Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- SK bioscience Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Valneva SE
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbott Laboratories
1. Global Flu Shots Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
2. Global Inactivated Influenza Vaccines (IIV) Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Recombinant Influenza Vaccines Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Flu Shots Market Research and Analysis by Formulation, 2025–2035 ($ Million)
5. Global Trivalent Flu Shots Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Quadrivalent Flu Shots Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Flu Shots Market Research and Analysis by Patient Group, 2025–2035 ($ Million)
8. Global Flu Shots For Pediatric Patients Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Flu Shots in For Adult Patients Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Flu Shots in For Geriatric Patients Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Flu Shots Market Research and Analysis by Region, 2025–2035 ($ Million)
12. North American Flu Shots Market Research and Analysis by Country, 2025–2035 ($ Million)
13. North American Flu Shots Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
14. North American Flu Shots Market Research and Analysis by Formulation, 2025–2035 ($ Million)
15. North American Flu Shots Market Research and Analysis by Patient Group, 2025–2035 ($ Million)
16. European Flu Shots Market Research and Analysis by Country, 2025–2035 ($ Million)
17. European Flu Shots Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
18. European Flu Shots Market Research and Analysis by Formulation, 2025–2035 ($ Million)
19. European Flu Shots Market Research and Analysis by Patient Group, 2025–2035 ($ Million)
20. Asia-Pacific Flu Shots Market Research and Analysis by Country, 2025–2035 ($ Million)
21. Asia-Pacific Flu Shots Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
22. Asia-Pacific Flu Shots Market Research and Analysis by Formulation, 2025–2035 ($ Million)
23. Asia-Pacific Flu Shots Market Research and Analysis by Patient Group, 2025–2035 ($ Million)
24. Rest of the World Flu Shots Market Research and Analysis by Region, 2025–2035 ($ Million)
25. Rest of the World Flu Shots Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
26. Rest of the World Flu Shots Market Research and Analysis by Formulation, 2025–2035 ($ Million)
27. Rest of the World Flu Shots Market Research and Analysis by Patient Group, 2025–2035 ($ Million)
1. Global Flu Shots Market Share by Vaccine Type, 2025 vs 2035 (%)
2. Global Inactivated Influenza Vaccines (IIV) Market Share by Region, 2025 vs 2035 (%)
3. Global Recombinant Influenza Vaccines Market Share by Region, 2025 vs 2035 (%)
4. Global Flu Shots Market Share by Formulation, 2025 vs 2035 (%)
5. Global Trivalent Flu Shots Market Share by Region, 2025 vs 2035 (%)
6. Global Quadrivalent Flu Shots Market Share by Region, 2025 vs 2035 (%)
7. Global Flu Shots Market Share by Patient Group, 2025 vs 2035 (%)
8. Global Flu Shots For Pediatric Patients Market Share by Region, 2025 vs 2035 (%)
9. Global Flu Shots For Adult Patients Market Share by Region, 2025 vs 2035 (%)
10. Global Flu Shots For Geriatric Patients Market Share by Region, 2025 vs 2035 (%)
11. Global Flu Shots Market Research and Analysis by Region, 2025–2035 ($ Million)
12. US Flu Shots Market Size, 2025–2035 ($ Million)
13. Canada Flu Shots Market Size, 2025–2035 ($ Million)
14. UK Flu Shots Market Size, 2025–2035 ($ Million)
15. France Flu Shots Market Size, 2025–2035 ($ Million)
16. Germany Flu Shots Market Size, 2025–2035 ($ Million)
17. Italy Flu Shots Market Size, 2025–2035 ($ Million)
18. Spain Flu Shots Market Size, 2025–2035 ($ Million)
19. Russia Flu Shots Market Size, 2025–2035 ($ Million)
20. Rest of Europe Flu Shots Market Size, 2025–2035 ($ Million)
21. India Flu Shots Market Size, 2025–2035 ($ Million)
22. China Flu Shots Market Size, 2025–2035 ($ Million)
23. Japan Flu Shots Market Size, 2025–2035 ($ Million)
24. South Korea Flu Shots Market Size, 2025–2035 ($ Million)
25. Australia and New Zealand Flu Shots Market Size, 2025–2035 ($ Million)
26. ASEAN Economies Flu Shots Market Size, 2025–2035 ($ Million)
27. Rest of Asia-Pacific Flu Shots Market Size, 2025–2035 ($ Million)
28. Latin America Flu Shots Market Size, 2025–2035 ($ Million)
29. Middle East and Africa Flu Shots Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Flu Shots Market in 2025 is estimated to be around $9.20 billion.
North America holds the largest share in the Flu Shots Market.
Leading players in the Flu Shots Market include CSL Ltd. (Seqirus), GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi, among others.
The Flu Shots Market is expected to grow at a CAGR of 7.2% from 2026 to 2035.
The Flu Shots Market growth is driven by increasing awareness of seasonal influenza prevention and rising government immunization programs and vaccination coverage initiatives.
